Latest Stock Buy or Sell? Make More Informed Decisions!

If an investor is not an owner today, wait until the announced reorganizations have been completed and then pick and choose the divisions that are suitable. He looks favorably on the coming aerospace division and the new Internet of Things division.

Comment on Uber. Uber just appointed a new CEO. In his view, this is a good sign as it moves toward an IPO. However, he does not buy any stock at the IPO. He thinks that new IPO’s are often mispriced and waits until the stock demonstrates a track record as a public company.

Comparing this to Citigroup: he owns both stocks. Both came out of the 2008 crisis in worse shape than the other large money center banks; both have recovered substantially and are trading at a narrower discount to them now. He expects the gap to close further. Citi trades at a greater discount and has more upside potential.

Comparing this to Citigroup: he owns both stocks. Both came out of the 2008 crisis in worse shape than the other large money center banks; both have recovered substantially and are trading at a narrower discount to them now. He expects the gap to close further. Citi trades at a greater discount and has more upside potential. The CEO at Citigroup keeps his head down, working on the company’s business. He doesn’t show up much in the press reports; he just does a good job. (Analysts’ price target is $83.04)

(A Top Pick September 19, 2017. Down 37%). About 70% of the stocks he buys turn into gains. Celgene was one of the losses. Generally, the goal is to cut losses quickly. However, Celgene’s earnings have been rising, not falling. The difference is that the market has lost confidence in the company and dropped the valuation from a premium level to an extreme discount. The company has had some missteps, failed drug trials, that pare down its long term growth. Looking at Celgene at today’s price, he is keeping it because it offers good value at this price.

(A Top Pick September 19, 2017. Up 7%). It went up quite a bit and has been coming back down because of trade issues. He expects it to rise again once the trade-related clouds blow over. The company’s growth rate is impressive and it trades at only 9x earnings.

(A Top Pick September 19, 2017. Up 2%). This is one of the most successful companies on the exchange. There are some issues for the company, coming out of its advertising. They are trying to remedy that to get higher margin growth. He thinks the company has a good future.

Comment on US Health Care. He thinks this was out of favor because of uncertainty about how President Trump would handle Obamacare. The sector has recovered as people realize that the government is not providing solutions; they are coming out of the industry instead.

This is a very positive company. This is a large US insurer, with a separate interest in health records and technology. The company has done very well but still trades at a reasonable valuation.

People often invest in dividend-paying consumer staples stocks for the dividend because the bond market currently pays so little. However, the money flow into these companies, in search of yield, has driven their prices up. However, as yields have started rising, people have been leaving these companies. Kraft Heinz has dropped 29% over the past year. Many other companies in this sector have dropped substantially. There are many other sources of value to a company than dividends, such as capital growth.

This is a fine company. Its primary product is Humira, the most successful drug in the history of the pharmaceutical industry. It represents about 60% of AbbVie’s earnings, which means that AbbVie’s portfolio is not well diversified. This is not unusual for pharma companies. The drug will not go off patent for a few years, but the clock is ticking. The question to ask is whether the company has good replacements in the works.

This is old technology. It was one of the greatest success stories, and is trying to reinvent itself, much like Cisco and Microsoft. Intel’s future is probably in the chips that will power artificial intelligence, such as autonomous driving. The company holds great promise but there are serious questions about whether they will be the leadership group. He thinks that there is more visibility in companies like Google and Apple and Facebook, whereas the future of Intel is still uncertain. (Analysts’ price target is $56.55)

It’s had a bumpy road, with the reputational risk that it has been addressing. This happens with all big companies. As they get large, third parties and governments get involved and pose new challenges. He does not expect much new regulation given the current attitudes toward intellectual property protection and free speech. They have 2 billion active monthly users, which is an advertiser’s dream. Along with monetizing their Facebook user base, they are monetizing other things such as Instagram, which is taking new technology forward. This illustrates that the traditional Facebook model has morphed, which is what successful companies do. Facebook was a high-valuation stock that has come down in valuation as both price and earnings have risen, because earnings have come up faster than price. He has trimmed his holdings of Facebook as its price has come up, to keep it from taking up too much space in his portfolio.

He has owned it for a long time. It has been a great holding. This is a juggernaut, they do over 1 trillion transactions per year, more than MasterCard and AMEX combined. They have taken ownership of Visa in Europe, where cash is still used more than in the U.S. This provides a big opportunity for expansion. Debit is now 60% of their business, and international is 60% of their business, these support rapid growth. Visa is not cheap but it is very stable and worth owning.

Eighteen percent of GDP goes to health in the United States, compared to 11% in Canada. CVS is trying to be a health solution to the US population and is well positioned to do it. Their purchase of Aetna gives them a large and strong insurance component. Caremark is a pharmacy benefits manager that gives them buying power with the drug companies and enables them to price their insurance favorably. They have 10,000 storefronts, a store within 3 miles of 70% of the population. CVS has been beaten down out of a fear that Amazon would take the business, but it is a large company of seasoned professionals in a highly regulated industry. They are not going to roll over for Amazon. Yield 2.7%. (Analysts’ price target is $85.95)